3 results
Approved WMOCompleted
The primary objective is to compare PFS after treatment with tabalumab, bortezomib, anddexamethasone to that of placebo, bortezomib, and dexamethasone in patients with relapsed/refractory MM.Secondary objectives will include comparison of treatment…
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
Approved WMORecruiting
We aim to develop and validate algorithms to quantify and track physical capacity and physical activity to be used as clinical trial endpoints for the development of pharmacological and non-pharmacological interventions for participants with COPD…